HK1149898A1 - Combinations of sapacitabine or cndac with dna methyltransferase inhibitors such as decitabine and procaine sapacitabine - Google Patents
Combinations of sapacitabine or cndac with dna methyltransferase inhibitors such as decitabine and procaine sapacitabineInfo
- Publication number
- HK1149898A1 HK1149898A1 HK11104122.0A HK11104122A HK1149898A1 HK 1149898 A1 HK1149898 A1 HK 1149898A1 HK 11104122 A HK11104122 A HK 11104122A HK 1149898 A1 HK1149898 A1 HK 1149898A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- sapacitabine
- cndac
- decitabine
- procaine
- combinations
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
- A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
- A61K31/245—Amino benzoic acid types, e.g. procaine, novocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Emergency Medicine (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0810552A GB0810552D0 (en) | 2008-06-09 | 2008-06-09 | Combination |
GB0906696A GB0906696D0 (en) | 2009-04-17 | 2009-04-17 | Combination |
PCT/GB2009/001418 WO2009150405A1 (en) | 2008-06-09 | 2009-06-05 | Combination of spacitabine (cndac) and dna methyltransferase inhibitors such as decitabine and procaine |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1149898A1 true HK1149898A1 (en) | 2011-10-21 |
Family
ID=40996776
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK11104122.0A HK1149898A1 (en) | 2008-06-09 | 2011-04-26 | Combinations of sapacitabine or cndac with dna methyltransferase inhibitors such as decitabine and procaine sapacitabine |
Country Status (12)
Country | Link |
---|---|
US (2) | US8530445B2 (xx) |
EP (1) | EP2307002B1 (xx) |
JP (2) | JP6006938B2 (xx) |
KR (1) | KR101667641B1 (xx) |
CN (1) | CN102088969B (xx) |
AU (1) | AU2009259136B2 (xx) |
CA (1) | CA2725295C (xx) |
ES (1) | ES2401951T3 (xx) |
HK (1) | HK1149898A1 (xx) |
NZ (1) | NZ589719A (xx) |
PL (1) | PL2307002T3 (xx) |
WO (1) | WO2009150405A1 (xx) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20110301110A1 (en) * | 2010-06-03 | 2011-12-08 | Aucagne Romain | TRIM33 (TIF1gamma) AS A NEW DIAGNOSTIC MARKER OF CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML) |
WO2012038417A1 (en) * | 2010-09-20 | 2012-03-29 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Substituted amino - benzoic acid derivatives as inhibitors of dna methyltransferases |
WO2012140436A1 (en) | 2011-04-14 | 2012-10-18 | Cyclacel Limited | Dosage regimen for sapacitabine and decitabine in combination for treating acute myeloid leukemia |
CA2854461C (en) * | 2011-11-03 | 2021-01-19 | Millennium Pharmaceuticals, Inc. | Administration of nedd8-activating enzyme inhibitor and hypomethylating agent |
JP6286421B2 (ja) * | 2012-05-15 | 2018-02-28 | サイクラセル リミテッド | サパシタビン及びセリシクリブの投与レジメン |
EP2961412A4 (en) | 2013-02-26 | 2016-11-09 | Triact Therapeutics Inc | CANCER THERAPY |
US9446064B2 (en) | 2013-03-14 | 2016-09-20 | Epizyme, Inc. | Combination therapy for treating cancer |
AU2013381886B2 (en) * | 2013-03-15 | 2018-08-16 | Epigenetics Pharma Llc | Fluorinated pyrimidine analogs and methods of use thereof |
CN103191144B (zh) * | 2013-04-25 | 2014-06-18 | 李伟丽 | 一种治疗癌症的药物组合物及应用 |
KR101486248B1 (ko) * | 2013-04-29 | 2015-01-27 | 숙명여자대학교산학협력단 | Dna 메틸화 저해제를 포함하는 상염색체 우성 다낭신 개선 또는 치료용 약학 조성물 |
JP6585041B2 (ja) * | 2013-07-18 | 2019-10-02 | ベイラー カレッジ オブ メディスンBaylor College Of Medicine | 免疫細胞の能力を増強する方法 |
CN103861107B (zh) * | 2014-03-04 | 2015-01-14 | 中国人民解放军总医院第一附属医院 | 一种药物组合物及其用途 |
AU2015252844A1 (en) * | 2014-05-02 | 2016-11-03 | Kay NOEL | Method of treating acute myeloid leukemia and/or acute lymphoblastic leukemia using thienotriazolodiazepine compounds |
US20180028552A1 (en) * | 2015-01-30 | 2018-02-01 | Epizyme, Inc. | Combination therapy for treating cancer |
CA2982928A1 (en) | 2015-04-20 | 2016-10-27 | Tolero Pharmaceuticals, Inc. | Predicting response to alvocidib by mitochondrial profiling |
EP3298021B1 (en) | 2015-05-18 | 2019-05-01 | Tolero Pharmaceuticals, Inc. | Alvocidib prodrugs having increased bioavailability |
US10568887B2 (en) * | 2015-08-03 | 2020-02-25 | Tolero Pharmaceuticals, Inc. | Combination therapies for treatment of cancer |
EP3362070B1 (en) * | 2015-10-15 | 2021-01-27 | Celgene Corporation | Combination of a mutant isocitrate dehydrogenase 2 inhibitor with azacitidine and its use for treating acute myelogenous leukemia |
TW201720459A (zh) * | 2015-11-02 | 2017-06-16 | 妮翠斯製藥公司 | Ntn1中和劑與抑制後生控制之藥物之組合治療 |
WO2018094275A1 (en) | 2016-11-18 | 2018-05-24 | Tolero Pharmaceuticals, Inc. | Alvocidib prodrugs and their use as protein kinase inhibitors |
CN110234659A (zh) | 2016-12-19 | 2019-09-13 | 特雷罗药物股份有限公司 | 用于敏感性分析的分析肽和方法 |
US11497756B2 (en) | 2017-09-12 | 2022-11-15 | Sumitomo Pharma Oncology, Inc. | Treatment regimen for cancers that are insensitive to BCL-2 inhibitors using the MCL-1 inhibitor alvocidib |
WO2019081951A1 (en) | 2017-10-27 | 2019-05-02 | Cyclacel Limited | DOSAGE REGIME |
KR20210099066A (ko) | 2018-12-04 | 2021-08-11 | 스미토모 다이니폰 파마 온콜로지, 인크. | 암의 치료를 위한 작용제로서 사용하기 위한 cdk9 억제제 및 그의 다형체 |
JP2022525149A (ja) | 2019-03-20 | 2022-05-11 | スミトモ ダイニッポン ファーマ オンコロジー, インコーポレイテッド | ベネトクラクスが失敗した急性骨髄性白血病(aml)の処置 |
WO2021079129A1 (en) | 2019-10-24 | 2021-04-29 | Cyclacel Limited | Dosing regimen |
US11957701B2 (en) | 2020-07-17 | 2024-04-16 | Delta-Fly Pharma, Inc. | Therapy and new therapeutic agent for blood cancer |
CN116284188A (zh) * | 2023-02-07 | 2023-06-23 | 南开大学 | 一种dna甲基转移酶dnmt1的双底物抑制剂及其应用 |
Family Cites Families (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2305815A1 (de) | 1973-02-07 | 1974-08-08 | Kurt Seuberth | Vorrichtung zum trennen von chirurgischen faeden |
DE7304511U (de) | 1973-02-07 | 1974-02-28 | Classen M | Vorrichtung zum trennen von faeden |
JP2559917B2 (ja) | 1990-06-15 | 1996-12-04 | 三共株式会社 | ピリミジンヌクレオシド誘導体 |
CA2079413C (en) | 1991-09-30 | 2003-09-09 | Masakatsu Kaneko | Pyrimidine nucleoside derivatives having anti-tumor activity, their preparation and use |
US5720745A (en) | 1992-11-24 | 1998-02-24 | Erbe Electromedizin Gmbh | Electrosurgical unit and method for achieving coagulation of biological tissue |
DE4419792C1 (de) | 1994-06-06 | 1996-02-01 | Alfons Prof Dr Med Hofstetter | Endoskop |
US5824984A (en) * | 1997-03-31 | 1998-10-20 | Morrow; John A. | Portable electric wire cutter |
GB9718913D0 (en) * | 1997-09-05 | 1997-11-12 | Glaxo Group Ltd | Substituted oxindole derivatives |
US6403632B1 (en) * | 2000-03-01 | 2002-06-11 | Bristol Myers Squibb Pharma Co | Lactam metalloprotease inhibitors |
US6835185B2 (en) * | 1998-12-21 | 2004-12-28 | Micrus Corporation | Intravascular device deployment mechanism incorporating mechanical detachment |
US6462063B1 (en) * | 2000-02-04 | 2002-10-08 | Fibrogen, Inc. | C-proteinase inhibitors |
US20020156033A1 (en) * | 2000-03-03 | 2002-10-24 | Bratzler Robert L. | Immunostimulatory nucleic acids and cancer medicament combination therapy for the treatment of cancer |
MY164523A (en) | 2000-05-23 | 2017-12-29 | Univ Degli Studi Cagliari | Methods and compositions for treating hepatitis c virus |
NZ547204A (en) | 2000-05-26 | 2008-01-31 | Idenix Cayman Ltd | Methods and compositions for treating flaviviruses and pestiviruses |
JP2003535907A (ja) * | 2000-06-22 | 2003-12-02 | ユニバーシティ オブ アイオワ リサーチ ファウンデーション | 抗体誘導性細胞溶解を促進し、そして癌を処置するための方法 |
WO2002028829A2 (en) | 2000-09-25 | 2002-04-11 | Questcor Pharmaceuticals, Inc. | Peptide deformylase inhibitors |
PT1411954E (pt) | 2000-10-18 | 2011-03-16 | Pharmasset Inc | Nucleosídeos modificados para o tratamento de infecções virais e proliferação celular anormal |
EP1360325A2 (en) * | 2000-10-18 | 2003-11-12 | Pharmasset Limited | Multiplex quantification of nucleic acids in diseased cells |
CA2430376A1 (en) | 2000-12-08 | 2002-06-13 | David J. Carini | Semicarbazides and their uses as cyclin dependent kinase inhibitors |
JP3748536B2 (ja) | 2001-02-09 | 2006-02-22 | 三共株式会社 | ピリミジンヌクレオシド誘導体の結晶 |
US6908906B2 (en) * | 2001-02-09 | 2005-06-21 | Sankyo Company, Limited | Crystalline forms of pyrimidine nucleoside derivative |
US6676692B2 (en) * | 2001-04-27 | 2004-01-13 | Intek Technology L.L.C. | Apparatus for delivering, repositioning and/or retrieving self-expanding stents |
ATE445400T1 (de) * | 2001-05-25 | 2009-10-15 | Bristol Myers Squibb Co | Hydantion-derivate als hemmer von matrix- metalloproteinasen |
US6949558B2 (en) | 2001-11-07 | 2005-09-27 | Yale University | Enhancement of taxane-based chemotherapy by a CDK1 antagonist |
US7137993B2 (en) | 2001-12-03 | 2006-11-21 | Xtent, Inc. | Apparatus and methods for delivery of multiple distributed stents |
US8383605B2 (en) * | 2002-07-30 | 2013-02-26 | Aeterna Zentaris Gmbh | Use of alkylphosphocholines in combination with antimetabolites for the treatment of benign and malignant oncoses in humans and mammals |
KR20060012622A (ko) | 2003-05-16 | 2006-02-08 | 하이브리돈, 인코포레이티드 | 화학요법제와 함께 이뮤노머를 사용하는 상승적 암 치료방법 |
US20050014716A1 (en) | 2003-05-21 | 2005-01-20 | Wang Jin Wei | Pancreatic cancer treatment |
GB0328180D0 (en) * | 2003-12-04 | 2004-01-07 | Cyclacel Ltd | Combination |
WO2006090931A1 (ja) * | 2005-02-28 | 2006-08-31 | Eisai R & D Management Co., Ltd. | スルホンアミド化合物の抗癌剤との新規併用 |
US20060212899A1 (en) * | 2005-03-17 | 2006-09-21 | Ryan Steelberg | System and method for broadcast tagging |
GB0523041D0 (en) | 2005-11-11 | 2005-12-21 | Cyclacel Ltd | Combination |
GB0526419D0 (en) | 2005-12-23 | 2006-02-08 | Cyclacel Ltd | Formulation |
GB0609530D0 (en) | 2006-05-12 | 2006-06-21 | Cyclacel Ltd | Combination |
EP2049106A2 (en) * | 2006-07-14 | 2009-04-22 | Astex Therapeutics Limited | Pharmaceutical combinations |
CN101185629A (zh) | 2007-12-14 | 2008-05-28 | 山东蓝金生物工程有限公司 | 一种治疗实体肿瘤的地西他滨缓释剂 |
-
2009
- 2009-06-05 NZ NZ589719A patent/NZ589719A/xx unknown
- 2009-06-05 PL PL09761954T patent/PL2307002T3/pl unknown
- 2009-06-05 AU AU2009259136A patent/AU2009259136B2/en not_active Ceased
- 2009-06-05 ES ES09761954T patent/ES2401951T3/es active Active
- 2009-06-05 EP EP09761954A patent/EP2307002B1/en active Active
- 2009-06-05 WO PCT/GB2009/001418 patent/WO2009150405A1/en active Application Filing
- 2009-06-05 KR KR1020107029580A patent/KR101667641B1/ko active IP Right Grant
- 2009-06-05 US US12/997,197 patent/US8530445B2/en not_active Expired - Fee Related
- 2009-06-05 CN CN2009801269703A patent/CN102088969B/zh not_active Expired - Fee Related
- 2009-06-05 JP JP2011512202A patent/JP6006938B2/ja not_active Expired - Fee Related
- 2009-06-05 CA CA2725295A patent/CA2725295C/en not_active Expired - Fee Related
-
2011
- 2011-04-26 HK HK11104122.0A patent/HK1149898A1/xx not_active IP Right Cessation
-
2013
- 2013-08-06 US US13/960,489 patent/US8975239B2/en active Active
-
2014
- 2014-12-12 JP JP2014251673A patent/JP2015071637A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
KR101667641B1 (ko) | 2016-10-20 |
EP2307002B1 (en) | 2013-01-02 |
CA2725295C (en) | 2016-11-08 |
US20110207692A1 (en) | 2011-08-25 |
AU2009259136B2 (en) | 2014-09-25 |
CA2725295A1 (en) | 2009-12-17 |
US8530445B2 (en) | 2013-09-10 |
JP6006938B2 (ja) | 2016-10-12 |
WO2009150405A8 (en) | 2010-06-03 |
EP2307002A1 (en) | 2011-04-13 |
ES2401951T3 (es) | 2013-04-25 |
JP2011522814A (ja) | 2011-08-04 |
AU2009259136A8 (en) | 2011-01-06 |
WO2009150405A1 (en) | 2009-12-17 |
JP2015071637A (ja) | 2015-04-16 |
US20140100187A1 (en) | 2014-04-10 |
AU2009259136A1 (en) | 2009-12-17 |
CN102088969B (zh) | 2013-06-12 |
PL2307002T3 (pl) | 2013-05-31 |
US8975239B2 (en) | 2015-03-10 |
KR20110036547A (ko) | 2011-04-07 |
CN102088969A (zh) | 2011-06-08 |
NZ589719A (en) | 2012-08-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1149898A1 (en) | Combinations of sapacitabine or cndac with dna methyltransferase inhibitors such as decitabine and procaine sapacitabine | |
HUS2300045I1 (hu) | 2-Fluor-2-deoxitetrahidrouridin mint citidin | |
NL301185I2 (nl) | Combinatie van daunorubicine en cytarabine | |
EP2274446A4 (en) | SYSTEMS AND METHODS FOR TWO SLOW STEP ENZYME POLYMERASE | |
ZA201103637B (en) | Compositions and methods for the assembly of polynucleotides | |
ZA201103515B (en) | Composition comprising polymer and enzyme | |
HK1144319A1 (en) | Compositions and methods of detecting tiabs | |
ZA201102972B (en) | Improved double block and bleed | |
ZA201106827B (en) | Substituted nucleoside and nucleotide analogs | |
EP2364161A4 (en) | COMPOSITIONS CONTAINING SATIOGENES AND METHODS OF USE | |
EP2207891A4 (en) | MATERIALS AND METHODS FOR GENERATING TRANSCRIPTS COMPRISING MODIFIED NUCLEOTIDES | |
EP2272010A4 (en) | SYSTEMS AND METHODS FOR IDENTIFYING BLOCKS FROM MULTIPLE SYNDICATION CONTENT PROVIDERS | |
EP2132334A4 (en) | METHODS AND COMPOSITIONS ASSOCIATED WITH DETECTION OF NUCLEIC ACIDS | |
EP2236557A4 (en) | HYDROPHILIC COMPOSITION WITH MOLD-RESISTANT EFFECT AND HYDROPHILIC ELEMENT | |
FR2940608B1 (fr) | Utilisation de monosaccharides et composition | |
ZA201101160B (en) | Benzoimidazole derivatives and glycogen synthase kinse-3 beta inhibitors containing the same | |
EP2246428A4 (en) | MODIFIED TRNA WITH NON-NATURAL NUCLEOTIDE AND USE THEREOF | |
EP2134352A4 (en) | WNT COMPOSITIONS AND METHODS FOR THEIR USE | |
SI2376101T1 (sl) | Efektorji beta-arestina in sestavki ter metode za njihovo uporabo | |
EP2142926A4 (en) | COMPOSITIONS AND METHODS OF DETECTION | |
EP2381780A4 (en) | COMPOSITIONS COMPRISING DECITABINE AND TETRAHYDROURIDINE AND USES THEREOF | |
EP2245942A4 (en) | COCOA AND SPIRULINE-CONTAINING COMPOSITION | |
IL207827A0 (en) | Apoaequorin-containing compositions and methods of using same | |
PL2368357T3 (pl) | Poprawa utrzymania bezpieczeństwa i integralności | |
ZA201004894B (en) | Nuctraceutical composition and methods of use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20210603 |